AN ECONOMIC EVALUATION OF DASATINIB (SPRYCEL®) IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN CENTRAL AND EASTERN EUROPE

被引：1
|
作者：
Nagy, B. [1 ]
Kutikova, L. [2 ]
Stastny, M. [2 ]
Vasile, K. [3 ]
Nagy, Zsolnai, I [5 ]
Mayer, J. [4 ]
机构：
[1] Healthware Consulting Ltd, Budapest, Hungary
[2] Bristol Myers Squibb Co, Prague, Czech Republic
[3] Bristol Myers Squibb Co, Bucharest, Romania
[4] Univ Hosp Brno, Brno, Czech Republic
[5] Bristol Myers Squibb Co, Budapest, Hungary
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66231-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A358 / A358
页数：1
相关论文
共 50 条
  • [1] Dasatinib (SPRYCEL®) in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP).
    Cortes, Jorge
    O'Brien, S.
    Jones, D.
    Borthakur, G.
    Giles, F.
    Nicaise, C.
    Kantarjian, H. M.
    BLOOD, 2006, 108 (11) : 613A - 613A
  • [2] Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
    Liu, Delong
    Matloub, Yousif
    Mulchopadhyay, Jaydip
    Liu, David
    Goldberg, Stuart L.
    BLOOD, 2008, 112 (11) : 741 - 741
  • [3] Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).
    Khoury, Hanna Jean
    Mauro, Michael J.
    Matloub, Yousif
    Chen, Tai-Tsang
    Bahceci, Erkut
    Deininger, Michael
    BLOOD, 2009, 114 (22) : 463 - 464
  • [4] Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
    Hochhaus, Andreas
    Cortes, Jorge E.
    Kim, Dong-Wook
    Pinilla-Ibarz, Javier
    le Coutre, Philipp D.
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Apperley, Jane F.
    Khoury, H. Jean
    Talpaz, Moshe
    DiPersio, John F.
    DeAngelo, Daniel J.
    Abruzzese, Elisabetta
    Rea, Delphine
    Baccarani, Michele
    Mueller, Martin C.
    Gambacorti-Passerini, Carlo
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Deininger, Michael W.
    Hughes, Timothy P.
    Goldman, John M.
    Shah, Neil P.
    Kantarjian, Hagop M.
    Guilhot, Francois
    BLOOD, 2013, 122 (21)
  • [5] Is Quality of Life (QOL) Predictive for Clinical Response in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients Treated with Dasatinib?
    Ionova, Tatiana
    Bulieva, Natalia
    Golenkov, Anatoly
    Gritsenko, Taras
    Kozlova, Lilia
    Kuchma, Galina
    Lomaia, Elza
    Machulaytene, Elena
    Nikitina, Tatiana
    Novitskaya, Natalia
    Usacheva, Elena
    Shneider, Tatiana
    Trifonova, Elena
    Vinogradova, Olga
    Zinkovskaya, Anna
    BLOOD, 2017, 130
  • [6] Dasatinib as initial therapy for patients with chronic myeloid leukemia (CML) in early chronic phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop
    O'Brien, Susan
    Luthra, Raja
    Jabbour, Elias
    Quintas-Cardama, Aflonso
    Borthakur, Gautam
    Ravandi, Farhad
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge
    CANCER RESEARCH, 2011, 71
  • [7] Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    O'Brien, Susan
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 740 - 741
  • [8] Opportunistic Infections Are Uncommon with Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
    Al-Ameri, Ali
    Kantarjian, Hagop
    Borthakur, Gautam
    Bahceci, Erkut
    Szatrowski, Ted
    Damokosh, Andrew
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 459 - 459
  • [9] Therapy of Early Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Lower Dose Dasatinib
    Naqvi, Kiran
    Cortes, Jorge
    Skinner, Jeffrey
    Jabbour, Elias
    Pemmaraju, Naveen
    Borthakur, Gautam
    Estrov, Zeev
    Bose, Prithviraj
    Thompson, Philip
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S15 - S16
  • [10] Molecular Responses to Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Michor, Franziska
    Olshen, Adam
    Gonen, Mithat
    Jones, Dan
    Rios, Mary Beth
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 1114 - 1115
12345